ADRB2 and cystic fibrosis: These results, which highlight the potential detrimental interaction between CFTR modulators and β2AR-agonists, suggest that long-term stimulation of these receptors can have negative clinical implications potentially relevant to most CF patients and that new therapeutic regimens have to be taken into account [68].